• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤通过将CD4+CD25-淋巴细胞转化来诱导调节性T细胞扩增,此过程不依赖胸腺和增殖。

Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.

作者信息

Valzasina Barbara, Piconese Silvia, Guiducci Cristiana, Colombo Mario P

机构信息

Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

出版信息

Cancer Res. 2006 Apr 15;66(8):4488-95. doi: 10.1158/0008-5472.CAN-05-4217.

DOI:10.1158/0008-5472.CAN-05-4217
PMID:16618776
Abstract

The CD25- and CD25+ CD4 T-lymphocyte compartments are tightly regulated. We show here that tumors break such balance, increasing the number of CD4+CD25+ T cells in draining lymph node and spleen but not contralateral node of tumor-bearing mice. Tumor injection in thymectomized and CD25-depleted mice shows that CD4+CD25+ T-cell expansion occurs even in the absence of the thymus and independently from proliferation of preexisting CD25+ T cells. These newly generated cells are bona fide regulatory T cells (T reg) in terms of Foxp3 expression and suppression of CD3-stimulated or allogeneic effector cell proliferation. Transfer of congenic Thy1.1 CD4+CD25- T cells, from mice treated or not with vinblastine, into tumor-bearing or tumor-free mice and analysis of recovered donor lymphocytes indicate that conversion is the main mechanism for acquiring the expression of CD25 and Foxp3 through a process that does not require proliferation. Although conversion of CD4+CD25- T cells for generation of T regs has been described as a natural process that maintains peripheral T-reg population, this process is used by the tumor for immune escape. The prompt recovery of T regs from monoclonal antibody-mediated CD25 depletion in tumor-bearing mice suggests attempts able to inactivate rather than deplete them when treating existing tumors.

摘要

CD25阴性和CD25阳性的CD4 T淋巴细胞区室受到严格调控。我们在此表明,肿瘤打破了这种平衡,增加了荷瘤小鼠引流淋巴结和脾脏中CD4+CD25+ T细胞的数量,但对侧淋巴结中则没有增加。在胸腺切除和CD25缺失的小鼠中注射肿瘤表明,即使在没有胸腺的情况下,CD4+CD25+ T细胞也会扩增,且独立于预先存在的CD25+ T细胞的增殖。就Foxp3表达以及对CD3刺激或同种异体效应细胞增殖的抑制而言,这些新产生的细胞是真正的调节性T细胞(Treg)。将来自经或未经长春碱处理的小鼠的同基因Thy1.1 CD4+CD25- T细胞转移到荷瘤或无瘤小鼠中,并对回收的供体淋巴细胞进行分析,结果表明转化是通过一个不需要增殖的过程获得CD25和Foxp3表达的主要机制。虽然CD4+CD25- T细胞转化生成Treg已被描述为维持外周Treg群体的自然过程,但肿瘤利用这一过程进行免疫逃逸。荷瘤小鼠经单克隆抗体介导的CD25缺失后Treg迅速恢复,这表明在治疗现有肿瘤时,尝试使其失活而非耗尽它们。

相似文献

1
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.肿瘤通过将CD4+CD25-淋巴细胞转化来诱导调节性T细胞扩增,此过程不依赖胸腺和增殖。
Cancer Res. 2006 Apr 15;66(8):4488-95. doi: 10.1158/0008-5472.CAN-05-4217.
2
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.CD4+CD25+调节性T细胞的耗竭促进荷胰腺癌小鼠的肿瘤特异性免疫反应。
Ann Surg Oncol. 2006 Sep;13(9):1252-8. doi: 10.1245/s10434-006-9015-y. Epub 2006 Sep 3.
3
Induction of eye-derived tolerance does not depend on naturally occurring CD4+CD25+ T regulatory cells.眼源性耐受的诱导不依赖于天然存在的CD4+CD25+调节性T细胞。
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1047-55. doi: 10.1167/iovs.05-0110.
4
Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.门静脉注射诱导的耐受中CD4+CD25+Foxp3+调节性T细胞增加。
Surgery. 2009 Jun;145(6):663-74. doi: 10.1016/j.surg.2009.01.016. Epub 2009 Apr 19.
5
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.全身性给予抗CD25单克隆抗体可安全增强小鼠胶质瘤的免疫力,而不会消除调节性T细胞。
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305. doi: 10.1158/1078-0432.CCR-06-0053.
6
CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.CD4+CD25+ T细胞既能抑制自身反应性T细胞的诱导,又能抑制其效应功能,代表了一类独特的免疫调节细胞谱系。
J Immunol. 1998 Feb 1;160(3):1212-8.
7
In vitro expanded CD4+CD25+Foxp3+ regulatory T cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation.体外扩增的CD4+CD25+Foxp3+调节性T细胞维持正常表型并抑制免疫介导的眼表炎症。
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5434-40. doi: 10.1167/iovs.08-2075. Epub 2008 Jul 24.
8
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.CD4+CD25+调节性T细胞抑制肿瘤免疫,但对环磷酰胺敏感,这使得对已形成肿瘤的免疫治疗具有治愈性。
Eur J Immunol. 2004 Feb;34(2):336-44. doi: 10.1002/eji.200324181.
9
TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.转化生长因子β1(TGF-β1)在不同的CD4 + T细胞亚群中调节叉头框蛋白3(Foxp3)的表达和调节活性。
J Leukoc Biol. 2007 Aug;82(2):335-46. doi: 10.1189/jlb.1006644. Epub 2007 May 2.
10
In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.当与白细胞介素-12基因转移相结合时,体内清除CD25 +调节性T细胞可导致B16F10黑色素瘤的肿瘤排斥反应。
Exp Dermatol. 2004 Oct;13(10):613-20. doi: 10.1111/j.0906-6705.2004.00198.x.

引用本文的文献

1
Immunotherapy in Head and Neck Cancer.头颈部癌症的免疫疗法
Cancer Treat Res. 2025;129:119-156. doi: 10.1007/978-3-031-97242-3_7.
2
ALOXE3 expression predicts poor prognosis and modulates immune infiltration in colon adenocarcinoma.ALOXE3表达预示着结肠腺癌的预后不良并调节免疫浸润。
World J Surg Oncol. 2025 Jul 23;23(1):296. doi: 10.1186/s12957-025-03939-3.
3
Development of therapeutic cancer vaccines based on cancer immunity cycle.基于癌症免疫循环的治疗性癌症疫苗的开发。
Front Med. 2025 Jul 14. doi: 10.1007/s11684-025-1134-6.
4
Tumor-infiltrating regulatory T cell: A promising therapeutic target in tumor microenvironment.肿瘤浸润调节性T细胞:肿瘤微环境中一个有前景的治疗靶点。
Chin Med J (Engl). 2024 Dec 20;137(24):2996-3009. doi: 10.1097/CM9.0000000000003450. Epub 2024 Dec 16.
5
Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization.通过 TGF-β1/IL-15 极化产生抑制性 NK 细胞亚群。
J Immunol. 2024 Jun 15;212(12):1904-1912. doi: 10.4049/jimmunol.2300834.
6
Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.头颈癌中的免疫逃逸策略:逃避、抵抗、抑制、招募。
Cancers (Basel). 2024 Jan 11;16(2):312. doi: 10.3390/cancers16020312.
7
Targeting FOXP3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental Breast Cancer.利用腺病毒载体靶向 FOXP3 肿瘤内在效应治疗实验性乳腺癌。
Viruses. 2023 Aug 25;15(9):1813. doi: 10.3390/v15091813.
8
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma.免疫疗法及与靶向疗法联合治疗晚期肝细胞癌
Cancers (Basel). 2023 Jan 20;15(3):654. doi: 10.3390/cancers15030654.
9
Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.结直肠癌中免疫检查点抑制剂耐药与免疫逃逸的关联
Front Oncol. 2022 Sep 30;12:987302. doi: 10.3389/fonc.2022.987302. eCollection 2022.
10
Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.结直肠癌浸润调节性 T 细胞:功能异质性、代谢适应及治疗靶点。
Front Immunol. 2022 Jul 8;13:903564. doi: 10.3389/fimmu.2022.903564. eCollection 2022.